Amplitude Ventures

Reverb Therapeutics is focused on creating innovative treatments for cancer and other diseases. The company specializes in developing cytokine therapies that aim to promote targeted immune activation while minimizing toxicity. By utilizing bispecific antibodies, Reverb Therapeutics localizes endogenous cytokines to immune cells within the tumor microenvironment. This approach addresses the toxicity challenges associated with exogenously delivered cytokines, allowing for a more effective use of the body's existing cytokines to target cancer cells. Through this strategy, Reverb Therapeutics seeks to improve outcomes for cancer patients and advance the healthcare sector's capabilities in cancer treatment.

Fluid Biomed is a medical device start-up dedicated to the development of an innovative implantable dissolving stent specifically designed for the treatment of brain aneurysms. Founded by a team of neurosurgeons, the company aims to enhance patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that promotes healing and minimizes the need for invasive surgical procedures. This revolutionary device gently redirects blood flow to facilitate the healing of weakened aneurysms, enabling physicians to treat patients efficiently and effectively while reducing the risk of complications such as stroke.

Nomic is a bioengineering company focused on making the human proteome as accessible as the human genome. The company is developing the nELISA, a next-generation platform for measuring proteins at high throughput and scale. Nomic provides scientists with protein profiling solutions, allowing them to determine the scope and scale of their experiments. Their platform features cost-effective measurement of protein data and integrates smoothly with industry-standard cytometers for high-throughput analysis. Additionally, Nomic's technology enables the development of custom protein panels, leveraging nanotechnology to use DNA as a versatile linker to address issues of cross-reactivity in protein measurement.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

Ability Biologics is a biotechnology company focused on developing innovative immune-modulating biotherapeutics to meet the pressing medical needs of patients suffering from cancer and autoimmune diseases. The company leverages an advanced platform that employs continuously learning artificial intelligence and a comprehensive database of antigen-antibody interactions. This technology enables the creation of potent and selective antibody therapeutics, aimed at addressing significant gaps in treatment options for these challenging health conditions. By prioritizing tailored solutions, Ability Biologics seeks to enhance patient outcomes and contribute to advancements in the field of immunotherapy.

Reverb Therapeutics is focused on creating innovative treatments for cancer and other diseases. The company specializes in developing cytokine therapies that aim to promote targeted immune activation while minimizing toxicity. By utilizing bispecific antibodies, Reverb Therapeutics localizes endogenous cytokines to immune cells within the tumor microenvironment. This approach addresses the toxicity challenges associated with exogenously delivered cytokines, allowing for a more effective use of the body's existing cytokines to target cancer cells. Through this strategy, Reverb Therapeutics seeks to improve outcomes for cancer patients and advance the healthcare sector's capabilities in cancer treatment.

Tentarix Biotherapeutics is focused on developing innovative protein therapeutics that address significant challenges in the treatment of cancer, autoimmune diseases, and other medical conditions. The company utilizes a protein engineering platform that employs synthetic biology to create multispecific binding molecules with unique combined bioactivities. By leveraging fully human antibody variable domains, Tentarix aims to enhance specificity and therapeutic activity, offering clinicians new approaches to treatment that were previously unattainable.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that focuses on developing and manufacturing tissue-based medicines aimed at treating inflammatory diseases. Founded in 2020, the company employs a proprietary tissue-based platform to accelerate the discovery of novel therapies, with a particular emphasis on immunology and dermatology. Evommune's approach seeks not only to alleviate the symptoms of inflammatory disorders but also to halt disease progression, thereby improving the quality of life for patients. Its pipeline includes initiatives targeting prevalent inflammatory conditions, with a commitment to advancing patient care by creating best-in-class treatment options. Through innovative strategies, Evommune aims to drive meaningful advancements in the field of inflammatory disease management.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.

Congruence Therapeutics is a biotechnology company focused on drug discovery for diseases associated with protein misfolding. By integrating computational and experimental approaches, the company develops novel small molecules aimed at treating rare diseases. Utilizing structural bioinformatics, computational chemistry, and machine learning, Congruence has established an in silico platform that facilitates the design and validation of pharmacological stabilizers. This innovative approach allows researchers to create targeted therapeutic options for conditions linked to protein misfolding, advancing the field of biotechnology and improving treatment outcomes for affected patients.

DrugBank is a developer of a comprehensive drug knowledge platform aimed at enhancing healthcare delivery and accelerating drug research. Its extensive database offers detailed information about drugs, their mechanisms of action, and interactions, which aids healthcare professionals in making informed decisions. The platform includes tools for drug search, interaction checking, allergy information, and drug labeling, facilitating precision medicine and clinical software applications. By integrating its knowledge base into various software solutions, DrugBank enables companies to leverage advanced insights and data science for drug discovery, helping to identify novel drug candidates and opportunities for drug repurposing. Additionally, DrugBank Online serves as a publicly available resource, offering limited datasets for academic and non-commercial researchers. With over 13,000 citations in academic publications, DrugBank is widely utilized by researchers and health professionals worldwide.

Celsius Therapeutics is a biotechnology company focused on developing precision medicines for patients with cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a team of scientists, technologists, computational biologists, clinicians, and drug hunters. Utilizing single-cell genomic analysis and machine learning techniques, Celsius Therapeutics aims to discover and create innovative therapies that can lead to significant improvements in patient outcomes. The company's research efforts are centered on identifying new drug candidates that address unmet medical needs in the therapeutic landscape.

Congruence Therapeutics is a biotechnology company focused on drug discovery for diseases associated with protein misfolding. By integrating computational and experimental approaches, the company develops novel small molecules aimed at treating rare diseases. Utilizing structural bioinformatics, computational chemistry, and machine learning, Congruence has established an in silico platform that facilitates the design and validation of pharmacological stabilizers. This innovative approach allows researchers to create targeted therapeutic options for conditions linked to protein misfolding, advancing the field of biotechnology and improving treatment outcomes for affected patients.

Gandeeva Therapeutics is a precision biotechnology company focused on developing innovative therapeutics by leveraging cryogenic electron microscopy and machine learning to target key protein-protein interactions. The company's structure-guided drug discovery platform includes target prediction and validation, hit identification through virtual and fragment library screening, and lead optimization. Gandeeva has established a strong preclinical oncology pipeline aimed at addressing challenging cancers with unique protein interaction modulators, including interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area, Canada, Gandeeva is dedicated to enhancing the drug discovery process and reducing the risk of late-stage clinical failures.

InVivo AI, founded in 2017 and based in Montreal, Canada, specializes in utilizing artificial intelligence to enhance pharmaceutical research and development, particularly in the area of preclinical toxicology. The company aims to streamline the drug discovery process by implementing advanced AI methods for molecular representation and de novo design, which allows for the creation of novel chemical compounds that can address complex biological challenges. Through its innovative platform, InVivo AI is positioned to significantly improve the efficiency and effectiveness of drug design, paving the way for breakthroughs in pharmaceutical science.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018, the company operates from locations in Israel, the Netherlands, and Boston. Its primary asset is Pridopidine, an oral drug candidate that has demonstrated an established safety profile and shows promise in treating various movement disorders and neurodegenerative diseases in both adults and children. Prilenia aims to enhance the functional capacity of patients, particularly those undergoing early hemodialysis, by addressing the underlying challenges posed by these conditions.

Thryv Therapeutics is a precision medicine company focused on developing innovative therapies for Long QT Syndrome and various arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, atrial fibrillation, and treatment-resistant cancers. Thryv Therapeutics is dedicated to creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to reduce the risk of sudden cardiac death and enhance the quality of life for affected patients. Through its targeted therapeutic development, the company seeks to provide effective solutions for serious cardiovascular and oncological conditions.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

Giiant Pharma is a preclinical-stage biotechnology company focused on developing innovative therapies for inflammatory bowel diseases (IBD). Utilizing its proprietary Precision Delivery technology platform, Giiant designs gut-restricted, tissue-specific small molecule drug therapeutics that target specific biological pathways in gastroenterology. The company's lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug, which aims to improve drug tolerability while enhancing therapeutic effects. By releasing its active form specifically in the colon, Giiant's approach allows for targeted treatment at the site of inflammation, potentially preventing the worsening of patients' conditions.

Notch Therapeutics Inc. is an immune cell therapy company focused on developing gene-edited allogenic T cell therapies for cancer treatment. Based in Toronto, Canada, the company utilizes a proprietary platform for induced pluripotent stem cell (iPSC) technology that allows for precision control of Notch signaling, which is essential for T cell development. This innovative approach addresses critical limitations in cell therapy development, enabling the design and manufacture of a consistent and limitless supply of therapeutic T cells. Notch Therapeutics aims to provide targeted treatments for conditions such as non-Hodgkin lymphoma, leukemia, and multiple myeloma, facilitating advancements in the treatment of complex disease systems. Established in 2018, the company is positioned at the forefront of next-generation cancer therapies.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

Xap Therapeutics is a biotechnology start-up based in Cambridge, established in 2017 by James Patterson, M.D., Ph.D. The company focuses on developing a synthetic biology-driven platform for cell therapeutics. This platform utilizes clustered regularly interspaced short palindromic repeats (CRISPR) technology to engineer induced pluripotent stem cells, which serve as a foundation for producing a specialized "chassis" cell. These chassis cells are further functionalized into various cell therapies through genetically engineered constructs. Xap Therapeutics aims to enhance the treatment of serious diseases, including autoimmunity and cancer, by leveraging its innovative approach to cell therapy.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on developing and commercializing etripamil for various cardiovascular conditions. Etripamil is a novel short-acting calcium channel blocker designed to be administered as a rapid-onset nasal spray, specifically targeting the termination of episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the treatment of PSVT and is also exploring its potential applications for atrial fibrillation, angina, and other related cardiovascular disorders. Founded in 2003, Milestone Pharmaceuticals aims to address unmet medical needs in cardiovascular disease management through innovative therapeutic solutions.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.

PHEMI Systems Corporation specializes in developing a comprehensive privacy, security, governance, and data management system optimized for Microsoft Azure. Founded in 2013 and based in Vancouver, Canada, the company focuses on the healthcare sector, offering the PHEMI Data Privacy Manager. This cloud-based platform addresses the critical need for healthcare organizations to secure, manage, and control access to sensitive information while ensuring compliance with privacy regulations. Built on a privacy-by-design architecture, PHEMI’s software facilitates data sharing and integrates seamlessly with numerous data sources, as well as popular data science and business analysis tools. The platform is designed to scale according to the organization's size and offers a flexible usage-based pricing model.

Shoebox develops validated iPad audiometers to help solve everyday problems faced by hearing health professionals and workplace safety managers. They offer solutions for occupational hearing testing. They offer validated online hearing screening, boothless diagnostic audiometers, and a comprehensive tele-audiology solution.

Imagia's mission is to leverage advances in artificial intelligence and accelerate the advent of accessible personalized medicine. The company's platform leverage advances in artificial intelligence to provide outcome-based structured clinical data and federated learning capabilities across multiple sources while preserving privacy, enabling clinicians to drive end-to-end discoveries of predictive, diagnostic, and prescriptive analytics.